MindMed Addresses Board Coup, Says It Has Two-Year Cash Runway

May 4, 2023 · Green Market Report

The company asked its shareholders to reject a slate of directors offered up by FCM MM Holdings.

Mind Medicine (MindMed) Inc. (Nasdaq: MNMD) (NEO: MMED) reported a net loss of $24.8 million for the first quarter ended March 31, compared with $18.5 million for the same period in 2022.

The company does not have revenue to report at this time.

Cash Levels

As of March 31, MindMed had cash and cash equivalents totaling $129.4 million, compared with $142.1 million at the end of December 2022. The company said it believes it has enough cash to fund its operating requirements into the first half of 2025.

The net cash used in operating activities was $13.3 million for the quarter, versus $12.9 million in the quarter that ended March 31, 2022.

“2023 is a critical year for MindMed, and we are well positioned to continue advancing our R&D pipeline toward multiple near-term milestones later this year,” said Robert Barrow, CEO and director of MindMed. “These include key data from our Phase 2b study of MM-120 for the treatment of generalized anxiety disorder, as well as from our Phase 2a proof-of-concept trial of repeated low-dose MM-120 in attention-deficit/hyperactivity disorder.”

The company also has a Phase 2a study evaluating MM-120 for attention deficit hyperactivity disorder that remains on track for late 2023 topline readout.

The company is developing MM-402, its proprietary form of MDMA for the treatment of core symptoms of autism spectrum disorder. The first clinical trial is expected this year.

Board Coup

MindMed also issued a letter to shareholders asking that they not vote for a slate of four director candidated offered up by FCM MM Holdings, an entity affiliated with Jake Freeman, Scott Freeman, and Chad Boulanger. Current management believes the group is unqualified to serve on the board.

“FCM is waging a proxy contest to take control of the company despite only owning a small percentage of our outstanding shares and failing to provide any realistic strategic plan for MindMed,” the letter read. “We believe that allowing FCM to harm the company’s current strategy and management team – who have been successfully executing our plan under your Board’s oversight – would put your investment at risk.”

The letter went on to say that management has met with the Freemans and Boulanger numerous times since August 2022 to evaluate FCM’s perspectives on the company and its strategic direction.

“In these discussions, it became abundantly clear that FCM does not understand MindMed’s business – which has significantly evolved since Scott Freeman left the company in 2020 – or the associated regulatory processes.”

The letter goes on to call out “ideas FCM floated in its August 2022 ‘Value Enhancement Plan’” as damaging to shareholder value.

“These proposals reflect a pronounced misunderstanding of FDA drug approval processes, an ignorance of the capital allocation and financing needs of a company at MindMed’s growth stage, and a disregard for what is in the best interests of all shareholders.” (Full Story)

Next Post

Teen Marijuana Use Has Been Declining Since Legal Dispensaries Started Opening, Federal CDC Study Shows

Even as more states have moved to legalize marijuana, rates of current and lifetime cannabis use among high school students have continued to drop, newly released federal data shows. The Centers for Disease Control and Prevention’s (CDC) Youth Risk Behavior…
Previous Post

Washington Governor Signs Interstate Marijuana Commerce Bill Into Law

The governor of Washington State has signed a bill to allow interstate marijuana commerce, pending a federal policy change. The legislation from Sen. Ann Rivers (R) cleared the legislature last month, and Gov. Jay Inslee (D) signed it into law on…
Random Post

North Carolina House Speaker Says Senate-Approved Medical Marijuana Bill Has ‘Better Chance Of Passing’ Than Ever Before

The top North Carolina House lawmaker says that medical marijuana legalization has “a better chance of passing this year than in any time in the past,” and he expects a Senate-passed reform bill to be taken up by his chamber’s…
Random Post

DEA Official Says New Rules Are Coming For Synthetic Cannabinoids, Including CBD And Delta-8 THC

The Drug Enforcement Administration (DEA) will soon be proposing new rules to clarify that synthetically manufactured cannabinoids like delta-8 THC are prohibited controlled substances. At the agency’s 2023 Supply Chain Conference earlier this month, Terrance Boos, chief of DEA’s Drug…
Random Post

Prince Harry Recalls Tripping on Mushrooms During Party at Courteney Cox's House: 'I Was a Chandler'

Prince Harry shares many personal stories in his sweeping memoir Spare — like the time he took magic mushrooms at Courteney Cox's Los Angeles home. The Duke of Sussex, 38, revealed in his bestselling book that he is a "Friends fanatic" and took comfort in the hit…
Random Post

Police in California city seize 1,500 pounds of illegal marijuana products

Police in Pomona, California, are investigating a business where they found 1,500 pounds of unlicensed marijuana products as well as electronic casino gaming consoles. The business also had an area dedicated to selling cannabis, The LeafDesk reported. According to the media outlet,…